Corrigendum: Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer

George, Daniel J;Saad, Fred;Cookson, Michael S;Saltzstein, Daniel R;Shore, Neal D;et.al.
(2024) Clinical Genitourinary Cancer — Vol. 22, n° 2, p. 367 (2024)

Files

2024_George_Clin_Genitourin_Cancer_Corrigendum.pdf
  • Open Access
  • Adobe PDF
  • 91.14 KB
  • https://creativecommons.org/licenses/by-nc-nd/4.0/
Download

Details

Authors
  • George, Daniel J
    Author
  • Saad, Fred
    Author
  • Cookson, Michael S
    Author
  • Saltzstein, Daniel R
    Author
  • Tombal, Bertrandorcid-logoUCLouvain
    Author
  • Shore, Neal D
    Author
Show more
Abstract
Corrigendum: Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer (Clinical Genitourinary Cancer (2023) 21(3) (383–392.e2), (S155876732300068X), (10.1016/j.clgc.2023.03.009))
Affiliations

Citations

  • APA
  • Chicago
  • FWB

George, D. J., Saad, F., Cookson, M. S., Saltzstein, D. R., Tutrone, R., Bossi, A., Brown, B., Selby, B., Lu, S., Buckley, D., Tombal, B., & Shore, N. D. (2024). Corrigendum: Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. Clinical Genitourinary Cancer, 22(2), 367. https://doi.org/10.1016/j.clgc.2023.12.006 (Original work published 2024)